Our Pricing

The Science Behind Cured Pharmacy's Mounjaro

Published on: June 03, 2026

Understanding the mounjaro science how it works uk reveals why this treatment achieves exceptional weight loss outcomes. Mounjaro (tirzepatide) represents a breakthrough in obesity medicine as the first dual GIP/GLP-1 receptor agonist licensed by the MHRA, activating two complementary hormone pathways that regulate appetite, blood glucose, and energy expenditure [1]. At Cured Pharmacy, we provide genuine UK-licensed Mounjaro from £124.99 with transparent pricing and expert clinical support from our UK-registered prescribers.

The Dual Receptor Mechanism: What Makes Mounjaro Different

Mounjaro contains tirzepatide, a novel dual agonist that simultaneously activates glucose-dependent insulinotropic polypeptide (GIP) receptors and glucagon-like peptide-1 (GLP-1) receptors [1]. This dual mechanism distinguishes it from single-pathway treatments like semaglutide (Wegovy) or liraglutide (Saxenda), which target only GLP-1 receptors.

GIP receptors enhance insulin secretion in response to food intake whilst reducing glucagon release, helping to normalise blood glucose levels. GLP-1 receptors slow gastric emptying, increase satiety signals to the brain, and further improve insulin sensitivity [2]. By activating both pathways, tirzepatide produces synergistic effects that result in greater weight reduction and metabolic improvements than single-receptor approaches.

The molecular structure of tirzepatide has been engineered to provide balanced activation of both receptor types whilst maintaining a once-weekly dosing schedule. This pharmacokinetic profile ensures sustained therapeutic levels throughout the week, supporting consistent appetite suppression and metabolic regulation [1].

Clinical Trial Evidence: SURPASS Programme Results

The SURPASS clinical trial programme provides robust evidence for Mounjaro's efficacy. In SURPASS-1, treatment-naïve participants achieved mean weight reductions of 7.0 kg, 7.8 kg, and 9.5 kg with the 5 mg, 10 mg, and 15 mg doses respectively over 40 weeks [3]. These results demonstrated dose-dependent weight loss alongside significant HbA1c improvements.

SURPASS-3 compared tirzepatide directly against insulin degludec in patients with type 2 diabetes. Participants receiving the 15 mg dose achieved an average body weight reduction of 11.2 kg (approximately 22.5% of baseline weight) over 72 weeks, whilst simultaneously achieving superior glycaemic control [3]. Importantly, 91% of participants on the highest dose achieved at least 5% weight loss, and 57% achieved at least 15% weight loss.

The SURMOUNT-1 trial specifically evaluated tirzepatide for weight management in adults without diabetes. Over 72 weeks, participants receiving 15 mg tirzepatide lost an average of 20.9% of their body weight compared to 3.1% in the placebo group [4]. These findings led to MHRA approval for weight management indications in the UK.

Long-Term Safety Profile

Across the SURPASS programme, the most commonly reported adverse events were gastrointestinal in nature, including nausea (17-22% of participants), diarrhoea (13-16%), and constipation (6-8%) [3]. These symptoms were generally mild to moderate in severity and diminished over time as patients adapted to treatment. Serious adverse events occurred at similar rates to comparator groups, supporting the favourable safety profile observed in clinical practice.

How Mounjaro Science Translates to Weight Loss

The dual receptor activation of tirzepatide influences multiple physiological processes that contribute to weight reduction. GLP-1 receptor stimulation slows the rate at which food moves from the stomach into the small intestine, prolonging feelings of fullness after meals and reducing between-meal hunger [2]. This mechanism helps patients naturally reduce caloric intake without experiencing the intense hunger that often undermines traditional dieting approaches.

GIP receptor activation appears to enhance the metabolic effects beyond simple appetite suppression. Research suggests GIP signalling may influence energy expenditure, fat metabolism, and insulin sensitivity in ways that complement GLP-1 activity [1]. This dual action explains why tirzepatide consistently produces greater weight loss than GLP-1-only treatments in head-to-head comparisons.

At the neurological level, both GIP and GLP-1 receptors are present in appetite-regulating regions of the hypothalamus. Tirzepatide's action on these central nervous system receptors modulates reward pathways associated with food intake, potentially reducing cravings and emotional eating behaviours [2]. This multi-level approach addresses both the physiological and behavioural aspects of weight management.

Metabolic Benefits Beyond Weight Loss

Clinical trials demonstrate that Mounjaro improves cardiovascular risk markers including blood pressure, lipid profiles, and inflammatory markers [3]. Participants in SURPASS trials showed reductions in systolic blood pressure averaging 5-7 mmHg and improvements in triglyceride levels. These metabolic benefits may contribute to long-term health outcomes beyond the visible effects of weight reduction, though cardiovascular outcome trials are ongoing.

Mounjaro vs Wegovy: Comparing the Science

Both Mounjaro (tirzepatide) and Wegovy (semaglutide) are injectable medications approved for weight management in the UK, but their mechanisms differ fundamentally. Wegovy activates only GLP-1 receptors, whilst Mounjaro activates both GLP-1 and GIP receptors simultaneously [1][5]. This distinction has measurable clinical implications.

In comparative analyses, tirzepatide demonstrates superior weight loss outcomes. The SURPASS-2 trial directly compared tirzepatide against semaglutide 1 mg, showing that all tirzepatide doses (5 mg, 10 mg, and 15 mg) produced greater weight reduction than semaglutide [6]. Participants on tirzepatide 15 mg lost an average of 5.5 kg more than those on semaglutide over 40 weeks.

Both medications share similar side effect profiles, predominantly gastrointestinal symptoms that typically improve with continued use. The choice between treatments depends on individual patient factors, treatment history, and clinical response. At Cured Pharmacy, our UK prescribers assess your medical history during your free consultation to recommend the most appropriate option, whether that's Mounjaro or an alternative like Wegovy or Saxenda.

Dosing Science: How Mounjaro Treatment Progresses

Mounjaro follows a structured dose escalation protocol designed to minimise gastrointestinal side effects whilst optimising therapeutic outcomes. Treatment begins with 2.5 mg once weekly for four weeks, serving as an initial tolerability dose that allows your body to adapt to GIP/GLP-1 receptor activation [1]. This starting dose is not therapeutically optimal but establishes baseline receptor engagement.

After the initial four weeks, the dose increases to 5 mg weekly, which represents the minimum therapeutic dose for weight management. Depending on individual response and tolerability, your prescriber may recommend further increases to 7.5 mg, 10 mg, 12.5 mg, or the maximum licensed dose of 15 mg [1]. Each dose increase occurs at four-week intervals, allowing sufficient time to assess efficacy and side effects.

The KwikPen delivery system used for Mounjaro contains pre-filled, single-dose pens that require no manual dose adjustment. Each pen delivers a precise subcutaneous injection into the abdomen, thigh, or upper arm. Patients rotate injection sites weekly to minimise local reactions. The once-weekly schedule aligns with tirzepatide's extended half-life of approximately five days, maintaining therapeutic drug levels throughout the dosing interval [2].

Treatment Duration and Maintenance

Weight loss typically becomes apparent within the first 8-12 weeks of treatment, with maximal effects observed after 60-72 weeks of continued use [4]. Clinical guidelines recommend ongoing treatment for sustained weight management, as discontinuation often results in weight regain. Your UK prescriber will review your progress regularly to ensure continued appropriateness and adjust your treatment plan as needed based on your individual response and weight management goals.

Accessing Mounjaro Through Cured Pharmacy

At Cured Pharmacy, we've streamlined access to Mounjaro whilst maintaining rigorous clinical standards. Our process begins with a free online consultation that takes under three minutes to complete. You'll answer questions about your medical history, current medications, weight management goals, and any contraindications that might affect prescribing decisions.

A UK-registered prescriber from our clinical team reviews every consultation individually. If Mounjaro is clinically appropriate for you, they'll issue a private prescription that our pharmacy team dispenses using genuine UK-licensed medication supplied through regulated channels. All Mounjaro pens are sourced directly from licensed wholesalers and stored in temperature-controlled facilities that comply with MHRA standards.

Your medication arrives in 100% discreet packaging with no external markings indicating contents. We offer transparent upfront pricing with no hidden consultation fees—Mounjaro starts from £124.99 depending on your prescribed dose. Our superintendent pharmacist, Tarun Kumar (GPhC 2233073), oversees all dispensing to ensure every patient receives authentic medication with appropriate counselling on administration technique, side effect management, and storage requirements.

If you have questions about the science behind Mounjaro or need support during treatment, our pharmacy team is available on (+44) 116 4646009. We're committed to providing not just medication access but ongoing clinical support that helps you achieve sustainable weight management outcomes based on the latest evidence-based approaches.

Scientific References

1. Frias, J. P., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519 [accessed 13 August 2026]
2. Nauck, M. A., & D'Alessio, D. A. (2022). Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction. Cardiovascular Diabetology, 21(1), 169. https://doi.org/10.1186/s12933-022-01604-7 [accessed 13 August 2026]
3. Ludvik, B., et al. (2021). Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet, 398(10300), 583–598. https://doi.org/10.1016/S0140-6736(21)01443-4 [accessed 13 August 2026]
4. Jastreboff, A. M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
5. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
6. Frías, J. P., et al. (2021). Efficacy and safety of tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet, 398(10295), 64–77. https://doi.org/10.1016/S0140-6736(21)01324-6 [accessed 13 August 2026]
7. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
8. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
9. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary, and weight loss outcomes depend on adherence to treatment alongside lifestyle modifications including diet and exercise.